RITUXIMAB Pharmacologic Class Indexing
- Class set ID
- 439e35e6-1bfc-4691-9b95-cf2f56c63ba3
- Version
- 2
- Effective date
- 20180813
- Type
- Indexing - Pharmacologic Class
Mapped DailyMed Labels#
Label, Manufacturer, Effective table| Label | Manufacturer | Effective | SPL version |
|---|
| These highlights do not include all the information needed to use RUXIENCE safely and effectively. See full prescribing information for RUXIENCE. RUXIENCE ® (rituximab-pvvr) injection, for intravenous use Initial U.S. Approval: 2019 RUXIENCE (rituximab-pvvr) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences bet | Pfizer Laboratories Div Pfizer Inc | Pfizer Ireland Pharmaceuticals Unlimited Company | Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC | Pfizer Manufacturing Belgium NV | Samsung Biologics Co., Ltd. | 20260408 | 11 |
| These highlights do not include all the information needed to use RITUXAN HYCELA safely and effectively. See full prescribing information for RITUXAN HYCELA. RITUXAN HYCELA ® (rituximab and hyaluronidase human) injection, for subcutaneous use Initial U.S. Approval: 2017 | Genentech, Inc. | F. Hoffmann-La Roche AG | Roche Diagnostics GmbH | Genentech, Inc | 20251215 | 21 |
| These highlights do not include all the information needed to use RIABNI safely and effectively. See full prescribing information for RIABNI. RIABNI ® (rituximab-arrx) injection, for intravenous use Initial U.S. Approval: 2020 RIABNI (rituximab-arrx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the | Amgen, Inc | 20250912 | 9 |
| These highlights do not include all the information needed to use TRUXIMA safely and effectively. See full prescribing information for TRUXIMA. TRUXIMA ® (rituximab-abbs) injection, for intravenous use Initial U.S. Approval: 2018 TRUXIMA (rituximab-abbs) is biosimilar to RITUXAN ® (rituximab). | Cephalon, Inc. | CELLTRION, Inc. | SGS Vitrology Limited | Samsung Biologics Co Ltd. | 20250618 | 15 |
| These highlights do not include all the information needed to use RITUXAN safely and effectively. See full prescribing information for RITUXAN. RITUXAN ® (rituximab) injection, for intravenous use Initial U.S. Approval: 1997 | Genentech, Inc. | Genentech, Inc. (Oceanside) | Genentech, Inc. (Hillsboro) | Roche Diagnostics | Roche Diagnostics GmbH | 20250106 | 36 |